Filed by Mylan N.V.
Pursuant to Rule 425 under the Securities Act of 1933
and deemed filed pursuant to Rule
14a-12
under the Securities Exchange Act of 1934
Subject Company: Mylan N.V.
Commission File No.:
333-199861
The following communications are being filed in connection with the proposed business combination between Mylan N.V. and Upjohn Inc., Pfizer Inc.s
off-patent
branded and generic established medicines business
Mylan (@MylanNews) posted the
following tweet on Twitter on August 6, 2019
We recently announced that Mylan will combine with Upjohn, a Division of Pfizer, creating A New
Champion for Global Health uniquely positioned to fulfill the worlds need for medicine. Visit http://championforglobalhealth.com for more important information.
Mylan posted the following message on LinkedIn on August 6, 2019
We recently announced that Mylan will combine with Upjohn, a Division of Pfizer, creating A New Champion for Global Health uniquely positioned to fulfill the
worlds need for medicine. Visit https://lnkd.in/e4NxG3R for more important information.
Mylan Investor Relations posted the following message
on LinkedIn on August 6, 2019
We recently announced that Mylan will combine with Upjohn, a Division of Pfizer, creating A New Champion for
Global Health uniquely positioned to fulfill the worlds need for medicine. Visit https://lnkd.in/e4NxG3R for more important information.
Forward-Looking Statements
This communication contains
forward-looking statements. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may include, without limitation, statements about the
proposed transaction, the expected timetable for completing the proposed transaction, the benefits and synergies of the proposed transaction, future opportunities for the combined company and products and any other statements regarding
Pfizers, Mylans and Newcos future operations, financial or operating results, capital allocation, dividend policy, debt ratio, anticipated business levels, future earnings, planned activities, anticipated growth, market
opportunities, strategies, competitions, and other expectations and targets for future periods. Forward-looking statements may often be identified by the use of words such as will, may, could, should,
would, project, believe, anticipate, expect, plan, estimate, forecast, potential, intend, continue,
target and variations of these words or comparable words. Because forward-looking statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking
statements. Factors that could cause or contribute to such differences include, but are not limited to: the parties ability to meet expectations regarding the timing, completion and accounting and tax treatments of the proposed transaction;
changes in relevant tax and other laws; the parties ability to consummate the proposed transaction; the conditions to the completion of the proposed transaction, including receipt of approval of Mylans shareholders, not being satisfied
or waived on the anticipated timeframe or at all; the regulatory approvals required for the proposed transaction not being obtained on the terms expected or on the anticipated schedule or at all; inherent uncertainties involved in the estimates and
judgments used in the preparation of financial statements and the providing of estimates of financial measures, in accordance with the accounting principles generally accepted in the United States of America (U.S. GAAP) and related
standards, or on an